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Methods: We used a weighted genetic risk score (GRS) from 21 non-APOE LOAD risk variants to
predict survival in the Adult Changes in Thought and the Health and Retirement Studies. We meta-
analyzed hazard ratios and examined models adjusted for cognitive performance or limited to partic-
ipants with dementia. For replication, we assessed the GRS-longevity association in the Cohorts for
Heart and Aging Research in Genomic Epidemiology, comparing cases surviving to age 90 years
with controls who died between ages 55 and 80 years.
Results: Higher GRS predicted mortality (hazard ratio5 1.05; 95% confidence interval: 1.00–1.10,
P 5 .04). After adjusting for cognitive performance or restricting to participants with dementia, the
relationship was attenuated and no longer significant. In case-control analysis, the GRS was associ-
ated with reduced longevity (odds ratio 5 0.64; 95% confidence interval: 0.41–1.00, P 5 .05).
Discussion: Non-APOE LOAD susceptibility loci confer risk for mortality, likely through effects on
dementia incidence.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Risk variants from 22 genes have been identified for late-
onset Alzheimer’s disease (LOAD) incidence. Of these,
apolipoprotein E ε4 (APOE ε4) has the largest effect [1].imer’s Association. This is an open access article under the CC BY-NC-ND
J. Mez et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 188-195 189Genome-wide association studies (GWASs) of longevity in
older adults have identified APOE ε4 as a risk factor for mor-
tality [2–4]. This risk may be partially mediated through
dementia incidence [5,6], as dementia is a leading cause of
mortality in older adults [7]. Given the association of both
APOE ε4 and dementia with mortality, we hypothesized
that other genetic variants associated with LOAD incidence
would also be associated with mortality in older adults. We
anticipated that cognitive function and dementia incidence
would mediate the relationship with mortality. In other
words, we expected that LOAD genetic risk variants would
increase risk for cognitive decline and LOAD dementia,
which would in turn increase risk for death (Fig. 1, solid ar-
rows).
Quantifying and explaining the link between LOAD ge-
netic risk and mortality is critical for genetic research on de-
terminants of LOAD incidence: severe survivor bias could
make it difficult to identify genetic variants that increase dis-
ease incidence or could falsely implicate genetic variants
that are not actually associated with disease incidence [8].
For example, LOAD cases who are APOE ε4 carriers may
be omitted from research because they declined faster and
died before study enrollment or disease ascertainment [9].
APOE has also been implicated in risk for other disease pro-
cesses including cardiovascular disease [10], so it may influ-
ence mortality via mechanism(s) other than dementia,
thereby introducing potential survivor bias in its relationship
with LOAD. By assessing whether non-APOE genes associ-
ated with LOAD are also associated with increased mortal-
ity, we can provide researchers with tools to systematically
evaluate the potential magnitude of survivor bias [11].
Here, we attempt to replicate the previously reported link
between APOE ε4 and mortality and, in novel analyses,
assess whether non-APOE loci, previously found to be asso-
ciated with LOAD incidence, are also associated with mor-
tality. Because the effect size for each non-APOE variant is
small, we estimate the combined genetic risk that each sub-
ject had for developing LOAD by calculating a genetic risk
score (GRS). In primary analyses in two longitudinal
population-based prospective cohort studies, the Adult
Changes in Thought (ACT) study and the Health and Retire-
ment Study (HRS), we assessed the GRS relationship with
time to death using survival analysis. In subsequent models,
we tested whether cognition or dementia mediated or moder-
ated the relationship between the GRS and mortality. We
conducted a follow-up, confirmatory case-control analysis1LOAD Genetic 
Risk Loci
Cognitive 
Impairment
LOAD 
Dementia Mortality
4
32
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Fig. 1. Conceptualmodel. Solid lines indicate hypothesized path. Dashed lines
indicate uncertain alternative paths. Selection bias (collider stratification bias)
in LOAD genetic studies may be present if both the direct path to mortality
and the indirect path through LOAD dementia exist. Abbreviation: LOAD,
late-onset Alzheimer’s disease.in the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE), comparing the GRS among
longevity cases age 90 years versus controls who died be-
tween ages 55 and 80 years. Our findings could suggest new
genetic risk loci for longevity, add insight into how LOAD
risk loci affect dementia incidence and disease course, and
provide reassurance that the effect estimates of these loci
on LOAD incidence do not suffer from selection bias.2. Methods
2.1. Study populations2.1.1. Adult Changes in Thought
The ACT cohort draws from a population base defined by
the Group Health membership; the Group Health is an inte-
grated healthcare delivery system in King County, WA. The
ACT study enrolled 3392 cognitively normal community-
dwelling adults 65 years or older in two enrollment phases
(n 5 2581 in 1994–1996 and n 5 881 in 2001–2003) and
initiated ongoing enrollments in 2004. After obtaining
informed consent, in-person biennial interviews assessed
participants’ demographic, medical history, and functional
status. ACT stopped assessing participants diagnosed with
dementia but still obtained mortality information. For the
current analyses, from 4131 individuals with ACT visits,
we excluded participants who self-reported to be Hispanic
or nonwhite (to avoid confounding from population stratifi-
cation; n 5 383) or who were not genotyped (n 5 1418).
This left an analytic sample of 2330 individuals.
2.1.2. Health and Retirement Study
The HRS is a nationally representative cohort study initi-
ated in 1992 with enrollments in 1992, 1993, 1998, 2004,
and 2010. The target population is all noninstitutionalized
adults in the contiguous United States aged 501 years. Bien-
nial interviews (or proxy interviews for decedent or severely
impaired participants) are available through 2012 [12]. Our
analyses used a subsample with genetic data collected in
2006 or 2008. From 20,662 individuals alive in 2006 with
HRSvisits, we excluded participants whowere not genotyped
(n5 8580), who self-reported to be Hispanic or nonwhite (to
avoid confounding from population stratification; n5 2894),
or who were under age 65 years (to mimic ACT; n 5 3224).
This left an analytic sample of 5964 individuals.
2.1.3. Cohorts for Heart and Aging Research in Genomic
Epidemiology
The CHARGE consortium includes participants from the
following studies: Rotterdam Study, Study of Osteoporotic
Fractures, Cardiovascular Health Study, Osteoporotic Frac-
tures in Men Study, Framingham Heart Study, Health and
Retirement Study, Age, Gene/Environment Susceptibility—
Reykjavik Study, Religious Orders Study, Rush Memory and
AgingProject, Invecchiare nelChianti,BaltimoreLongitudinal
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Family Study, and European Union Longevity Consortium.
The current analysis includes the same participants as a case-
control GWAS of longevity reported previously [13]. Only
the participants of European ancestry were included. There
were 6036 cases, defined as participants who reached age
90 years, and 3757 controls, defined as participants who
died between the ages of 55 and 80 years.
All individuals were recruited under the protocols
approved by the appropriate Institutional Review Boards.2.2. Measures2.2.1. GRS for LOAD
Genotyping, imputation, and derivation of principal com-
ponents to control for population substructure are described
in the SupplementaryMethods, and further details have been
described previously for ACT [14], HRS [15], and CHARGE
[13].
In ACT and HRS, we generated a weighted GRS for
LOAD based on the effect size of single-nucleotide polymor-
phisms (SNPs) that achieved genome-wide significance.
Twenty-one genetic loci, other than APOE, have been
confirmed as genome-wide significant predictors of LOAD,
withmeta-analyzed odds ratios (ORs) reportedmost recently
in the Lambert et al. meta-analysis [1]. Because some of the
reported SNPs from Lambert et al. could not be confidently
imputed, we used proxy SNPs (two in ACT; four in HRS)
in high linkage disequilibrium (r2 . 0.8) identified using
SNP Annotation and Proxy Search [16]. Supplementary
Table 1 shows the SNPs used in each cohort and the respec-
tive b coefficients from the Lambert et al. meta-analysis. We
calculated the GRS by multiplying each individual’s pre-
dicted risk allele count for each locus by the b coefficient (ex-
pressed as the log OR) for that polymorphism as reported by
Lambert et al. and summing the products for all 21 loci. This
step weights each SNP in proportion to its anticipated effect
on LOAD risk. Finally, we standardized the GRS using each
sample’smean and standard deviation so that eachGRS had a
mean of 0 and a standard deviation of 1.
2.2.2. Mortality
In ACT, we usedmortality information obtained via death
certificates, state death registry data, annual telephone con-
tact with family members of study participants with demen-
tia, quarterly mailings to participants, and thorough review
of local obituaries. In HRS, we used mortality information
obtained via National Death Index linkage from 2008 to
2012. Information from proxy interviews was used for indi-
viduals without National Death Index information.
2.2.3. Cognitive performance
In ACT, cognitive performance was assessed using the
Cognitive Abilities Screening Instrument (CASI) [17].
Raw scores range from 0 to 100, with higher scoresindicating better performance. Because of concerns about
nonlinear scaling, we used CASI scores that were previously
derived using the item response theory [18]. In HRS, we
used a previously developed memory composite score
combining direct and proxy memory assessments for longi-
tudinal analyses. All HRS participants who were inter-
viewed directly were asked to complete an immediate and
delayed recall test based on a 10-word list. For individuals
too impaired to directly participate in memory assessments,
the informants, typically spouses, assessed the participants’
memory on a 5-item Likert scale and completed a 16-item
version of the Informant Questionnaire for Cognitive
Decline (IQCODE). We used an algorithm to integrate direct
and proxy assessments to retain severely impaired individ-
uals in longitudinal studies of cognitive function. The com-
posite score was derived in an 856-subject subsample who
participated in a comprehensive neuropsychological battery
as part of the Aging, Demographics, and Memory Study and
then uses regression models to calibrate the direct and proxy
reports from the prior HRS core interview to predict the Ag-
ing, Demographics, and Memory Study outcomes. We then
apply these prediction rules to estimate memory in the entire
HRS sample [19]. We standardized the memory score by
dividing each score by the 1995 standard deviation so that
every unit change in memory score corresponded to one
standard deviation in the population before baseline.
2.2.4. Dementia diagnosis in ACT
At baseline and every 2 years, ACT participants were
administered the CASI. Those with raw scores below 86
received a diagnostic evaluation that included physical and
neurological examinations, neuropsychological testing,
and laboratory studies, if not already available. A consensus
panel, which included study physicians, a neuropsychologist
and a research nurse, determined whether these participants
met criteria for dementia based onDiagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
criteria [20]. Participants remained in the cohort until they
were diagnosed with dementia or, if not demented, were
censored as a result of death or discontinuation of participa-
tion in the study.
2.2.5. Covariates
All models that included ACTand HRS participants were
adjusted for time constant covariates: sex, intake age, intake
age2, wave of genetic data collection, and the first three (in
ACT) or six (in HRS) principal components used to adjust
for population substructure in genetic analyses.2.3. Analytic plan
In ACT, we used Cox proportional hazards models to es-
timate the association between the GRS and APOE ε4 with
dementia onset date. We did not evaluate this relationship in
HRS because we recently published these analyses for HRS
separately, reporting that the GRS and APOE ε4 both
Table 1
Baseline characteristics of the ACT and HRS samples
Characteristics ACT (N 5 2330) HRS (N 5 5964)
Age, mean (SD) 75.1 (6.56) 74.8 (7.0)
Male, N (%) 1035 (44.4) 2616 (43.9)
GRS, mean (SD) 0.0 (1.0) 0.0 (1.0)
APOE ε4, N (%) 599 (25.7) 1534 (25.7)
CASI score at baseline
visit, mean (SD)
0.32 (0.71)
Memory score at baseline
visit, mean (SD)
0.89 (0.47)
Abbreviations: ACT, Adult Changes in Thought; CASI, Cognitive Abil-
ities Screening Instrument; GRS, genetic risk score; HRS, Health and
Retirement Study; SD, standard deviation.
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Next, in ACT and HRS, we used Cox models to estimate
the independent effects of the GRS and APOE ε4 on time
to death. We used time from study baseline as the timescale
in the Cox models. In subsequent models in both ACT and
HRS, we adjusted for cognitive performance using either
time-dependent CASI-item response theory in ACT or
time-dependent memory score in HRS. To further explore
the role of dementia in explaining the link between the
GRS and mortality, we stratified follow-up time for ACT
participants by dementia diagnosis. We defined the
dementia-free group as anyone who had not been diagnosed
with dementia by the current visit, even if they were diag-
nosed at a later date. Our dementia-diagnosed group was
defined as anyone with a dementia diagnosis at the current
or previous visit, and in these analyses, follow-up time for
the Cox models began at diagnosis instead of study baseline.
Therefore, some people contributed person-time to both cat-
egories, that is, before and after diagnosis. If dementia inci-
dence was the primary mechanism linking the GRS to
mortality, wewould not expect the GRS to have a large effect
on mortality in either the dementia-free or the dementia-
diagnosed groups, assuming no misclassification.
We meta-analyzed the estimated effect of the GRS on time
to death in ACTand HRS from both the unadjusted model and
themodel adjusting for time-dependent cognitiveperformance,
using a fixed effects model with inverse variance weights, as
implemented in the metan package in Stata 11.2 [22].
In CHARGE, because individual-level data were not
available, we reanalyzed the published summary statistics
including ORs and standard errors from a case-control
GWAS meta-analysis of longevity in CHARGE participants
of European ancestry [13]. We estimated the coefficient “a”
for the GRS as a linear predictor of longevity as follows:
ba y Pmi51WibbiS22iPm
i51W
2
i S
22
i
with a standard error estimate of
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where i indexes the SNPs in the GRS, wi is the parameter es-
timate of SNP i on the log odds of LOAD status, bbi is the
parameter estimate of SNP i on the log odds of longevity sta-
tus, and si is the standard error of bbi [23,24].
3. Results
Characteristics from the first wave in which each individ-
ual contributed an observation are shown for the 2330 ACT
sample members and 5964 HRS sample members used in
our models (Table 1). Average follow-up time was 8.6 years
(up to 18 years) in ACTand 4.6 years (up to 6 years) in HRS.
In ACT, 1267 (54.4%) participants died during the study,whereas 705 (11.8%) died in HRS. When we limited the
follow-up time in ACT to match HRS (i.e., 6 years), 561
(23.7%) participants died. Characteristics of each cohort
from the CHARGE consortium have been described
previously [13].
In ACT, both the GRS (hazard ratio [HR] 5 1.27; 95%
confidence interval [CI]: 1.14–1.41) and APOE ε4
(HR5 1.98; 95% CI: 1.62–2.43) predicted time to dementia
onset. Using Cox models, we found a significant association
between higher GRS and time to death, but not between
APOE ε4 and time to death (Table 2). In models adjusted
for time-dependent CASI score, the association between
the GRS and time to death was attenuated by more than
half and was no longer significant. In addition, we found
no evidence that the GRS predicted time to death when re-
stricting analyses to either individuals with or individuals
without a dementia diagnosis.
In HRS, the association between the GRS and time to
death was not statistically significant, although the 95% CI
included the point estimate from the ACT model. The point
estimate in HRSwas attenuated by about half when the time-
dependent memory score was included in the model,
although the absolute change was small from a point esti-
mate of 1.02 to 1.01 (Table 3). We found no evidence of
an association between APOE ε4 and time to death.
In the meta-analysis of the ACTand HRS results from the
models unadjusted for cognitive performance, there was a
significant association between the GRS and time to death
(Table 4). In the meta-analysis of the models adjusted for
time-dependent cognitive performance, we found that the
point estimate was attenuated by about 60% and was no
longer statistically significant. Using GWAS summary sta-
tistics for longevity from the CHARGE [13] and for
LOAD from the Lambert et al. meta-analysis [1], we found
an OR of 0.64 (95% CI: 0.41–1.00), suggesting the GRS
reduced chances of living past age 90 years.4. Discussion
In the ACT study, we found that a GRS based on 21 non-
APOE loci that achieved genome-wide significance in a
Table 2
Hazard ratios and 95% confidence intervals for GRS and APOE ε4 status on time to death in the ACT study
Predictors
Pooled analyses (N 5 2330)
Stratified analyses
Predementia diagnosis
(N 5 2330)
Postdementia diagnosis
(N 5 526)
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
AD-GRS 1.07 (1.01–1.14) .03 1.03 (0.96–1.09) .43 1.04 (0.97–1.12) .25 0.98 (0.88–1.10) .73
APOE ε4 (yes/no any ε4 alleles) 1.03 (0.91–1.17) .64 0.88 (0.78–1.01) ,.001 0.87 (0.74–1.03) .10 0.83 (0.67–1.03) .09
CASI score 0.59 (0.55–0.62) .07
Abbreviations: ACT, Adult Changes in Thought; AD-GRS, Alzheimer’s disease genetic risk score; CASI, Cognitive Abilities Screening Instrument; CI, con-
fidence interval; HR, hazard ratio; SD, standard deviation.
NOTE. All models were adjusted for sex, intake age and age2, wave of genetic data collection, and the first three principal components of population sub-
structure. Models include pooled analyses with and without adjustment for time-dependent CASI score and dementia-stratified analyses.
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reduced time to death, and this association was largely ex-
plained by cognitive function or dementia incidence.
Although the GRS was nonsignificantly associated with
higher mortality in the HRS sample, adjusting for cognitive
performance attenuated the association to a similar magni-
tude, as in ACT, albeit the absolute change was quite small.
In addition, the meta-analysis of ACTand HRS supported an
association between the GRS and time to death and an atten-
uation of that association with adjustment for time-
dependent cognitive performance. As confirmation of the
unadjusted result, we found that the GRS predicted reduced
odds of surviving to age 90 years (compared to dying be-
tween the ages of 55 and 80 years) in participants in the
CHARGE Consortium.
We investigated whether the GRSwas related to mortality
because APOE ε4, the largest risk allele for LOAD, has
consistently been identified as a risk factor for death in the
GWAS of longevity [2–4]. The heritability of longevity
has been estimated to be approximately 20% to 30%;
however, as with many complex traits, genetic risk factors
for longevity identified through GWAS only account for a
small portion of the predicted heritability, suggesting other
loci also contribute [25]. Our findings suggest that LOADTable 3
Hazard ratios and 95% confidence intervals for GRS and APOE ε4 status on
time to death in the HRS study (N5 5964), with and without adjustment for
time-dependent memory score
Predictors
Model 1
P-value
Model 2
P-valueHR (95% CI) HR (95% CI)
AD-GRS 1.02 (0.95–1.10) .64 1.01 (0.94–1.08) .86
APOE ε4 (yes/no
any ε4 alleles)
1.08 (0.91–1.27) .41 1.00 (0.85–1.19) .96
Memory score 0.46 (0.38–0.56) ,.001
Abbreviations: AD-GRS, Alzheimer’s disease genetic risk score; CI, con-
fidence interval; HR, hazard ratio; HRS, Health and Retirement Study.
NOTE. Both models were adjusted for sex, intake age and age2, wave of
genetic data collection, and the first six principal components of population
substructure.risk loci other than APOE ε4 may contribute to the heritabil-
ity of longevity, most likely via their influence on dementia
incidence.
Although most genetic studies of longevity have used a
case-control design, comparing long-lived “cases” with
younger “controls”, a few studies have used survival analysis
in a community-based cohort. These survival studies have
allowed for investigation of whether dementia status medi-
ates the effect of APOE ε4 on longevity, but results have
been inconsistent. Two smaller studies showed that dementia
mediates the relationship [5,6], whereas a larger meta-
analysis of several cohorts did not show evidence of media-
tion [26]. APOE ε4 has also been implicated in risk for other
disease processes including cardiovascular disease [10], so it
may influence longevity via mechanism(s) other than de-
mentia. In our study, we found an estimated effect of the
GRS on mortality, but we did not find statistically significant
associations between APOE ε4 and mortality in either ACT
or HRS. The lack of association with APOE ε4 may reflect
the older age of the ACT and HRS samples considered
here, as carriers may not have been included because they
were already impaired by age 65 years. Of note, the HRS be-
gins enrollment at age 50 years, and when we included all
genotyped participants (rather than just those age .65 to
mimic ACT), APOE ε4 still was not significantly associated
with mortality. Another possibility is that we were simply
underpowered to detect an association. Although CIs
describing the association between APOE ε4 and mortality
in ACT (0.91, 1.17) and in HRS (0.91, 1.27) were consistent
with increases in mortality, the previous longevity studies re-
ported point estimates larger than the upper bounds of these
CIs. A third possibility is true heterogeneity of effects of
APOE across populations, for reasons that remain to be
discovered.
The estimated effect of the GRS on mortality was atten-
uated by adjusting for cognition, providing evidence that
the GRS influences mortality primarily through cognition
(Fig. 1, arrows 1–3, 5). Collider stratification bias, a type
of survival bias that can occur when stratifying on a variable
in a causal system that is a shared effect of more than one
Table 4
GRS survival meta-analysis and longevity case/control analysis
Studies N
Model 1 Model 2
Effect size* (95% CI) P-value Effect size* (95% CI) P-value
Survival meta-analysis (ACT and HRS) 7294 1.05 (1.00–1.10) .04 1.02 (0.97–1.07) .47
Longevity case/controly (CHARGE) 9793 0.64 (0.41–1.00) .05
Abbreviations: ACT, Adult Changes in Thought; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology; CI, confidence interval; GRS,
genetic risk score; HR, hazard ratio; HRS, Health and Retirement Study; OR, odds ratio.
NOTE. Model 2, but not Model 1, was adjusted for time-dependent cognitive performance.
*HRs for survival models and OR for case/control model. Note HRs and ORs are not on the same scale and cannot be directly compared.
yControls (died between the ages of 55 and 80 years) are the reference group.
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netic studies of LOAD but has rarely been formally assessed.
Because genes can influence mortality through more than
one mechanism (pleiotropy), genetic studies of late-life
health outcomes, which by default stratify on survival (i.e.,
only those who have survived can be studied), may suffer
from collider stratification bias [8]. This study provides ev-
idence that collider stratification bias is less likely to be a
large concern in genetic studies of LOAD. Because most
of the effect of the GRS on mortality was through cognition
(Fig. 1, arrows 1–3, 5) and not an alternative pathway (Fig. 1,
arrow 4), there is less likely to be substantial collider strati-
fication bias.
When we limited our survival analysis to those with a de-
mentia diagnosis, the effect of the GRS on mortality was
attenuated (from an HR of 1.07 to 0.98), suggesting that
the risk score is not associated with differential mortality
among patients with dementia. Although the genetic profile
increases risk of developing dementia, and mortality is
known to be higher in dementia patients, patients with de-
mentia who carry high-risk genetic profiles do not have
higher mortality risk than patients with dementia without
high-risk genetic profiles. This is consistent with a
genome-wide survival analysis of mortality among LOAD
cases that found that the top nominally significant loci
(none achieved genome-wide significance) were not the
loci identified in LOAD case-control GWAS [28]. The esti-
mated effect of the GRS on mortality among people without
a diagnosis of dementia (some of whom likely had undiag-
nosed disease) was about half as large as the unstratified es-
timate (from an HR of 1.07 to 1.04) and not statistically
significant. Although larger data sets are necessary to more
precisely quantify the effect of the GRS on mortality in
dementia-free individuals, this result suggests that a fraction
of the mortality risk is related to cognitive deterioration
before diagnosis of dementia (Fig. 1, arrows 1 and 5).
One of the strengths of our study is the use of a GRS,
which is a valuable tool for assessing the cumulative predic-
tive capacity of genetic variation. We derived the GRS based
on variants that achieved genome-wide significance in the
largest LOAD meta-analysis to date (25,580 cases and
48,466 controls) [1].Weweighted each variant’s contribution
to the GRS based on its effect size in the GWAS, an approachthat has been shown to improve power to detect an associa-
tion compared with an unweighted approach [24]. Another
strength is that we were able to show suggestive association
of the GRS with longevity using two different ap-
proaches—a survival analysis in two epidemiological co-
horts and a case-control approach comparing long-lived
cases and younger controls. An epidemiological cohort is
the ideal setting to carry out unbiased evaluations of longitu-
dinal relationships [29]. Here, it allowed us to investigate the
mechanism by which the GRS affects mortality.
Important limitations of this study include the possibility
that people with prodromal LOAD were at higher mortality
risk before diagnosis, as suggested by the nonsignificant but
slightly elevated mortality risk associated with the GRS
among people without a dementia diagnosis in ACT. This
is partially mitigated by the ACT study practice of
decreasing the time between visits from 2 years to 1 year
for participants with impaired CASI scores who do not
meet criteria for dementia, so that they can be followed
more closely. Another limitation is that we did not replicate
in HRS the association of the GRS with mortality that we
observed in ACT. However, the HRS genetic cohort had
accumulated a relatively small number of deaths at the
time of this analysis, leading to wide CIs; the HRS and
ACT results were consistent based on the CIs. In addition,
the CHARGE case-control analysis provided confirmation
(if not true replication) of the ACT finding. The CHARGE
consortium longevity case-control analysis included 785
HRS participants (out of 9793 total participants), many of
whom were likely included in our HRS survival analysis.
Unfortunately, it was not possible to conduct CHARGE an-
alyses without these individuals. A further limitation is that
we could only examine genetic variants that have been
shown to predict LOAD; to the extent that survivor bias is
severely affecting LOAD GWAS, some important genetic
risk factors for LOAD may not yet have been identified.
There is no straightforward solution to this problem, but it
suggests the potential value of evaluating sensitivity to sur-
vival bias in the primary GWAS. Finally, we note that the
lack of evidence for a pathway from the GRS to mortality
that does not go through cognitive decline is not necessarily
evidence for the absence of the pathway. Rather, we may not
have power to detect a small effect.
J. Mez et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 188-195194In conclusion, we found that a non-APOE LOAD GRS is
associated with mortality and that this relationship may be
mediated by cognitive changes before dementia diagnosis.
Our study identifies new genetic risk factors for longevity
and provides insight into the mechanism by which they
may act. It also provides evidence that collider stratification
bias is unlikely to be a large concern in genetic studies of
LOAD. Future studies that are better powered should inves-
tigate the role of LOAD genetic risk factors on mortality
among nondemented older individuals.
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1. Systematic review: We searched PubMed to identify
relevant publications. References that contextualize
the hypothesis, methodology, and findings are cited.
To our knowledge, no previous study has analyzed
the relationship between the cumulative effect of
non-APOE late-onset Alzheimer’s disease (LOAD)
genetic risk variants and mortality.
2. Interpretation: Our findings suggest new genetic risk
loci for longevity, add insight into how LOAD risk
loci affect dementia incidence and disease course,
and provide reassurance that the effect estimates of
these loci on LOAD incidence do not suffer from se-
lection bias.
3. Future directions:Wefind that a fraction of themortal-
ity risk fromLOAD risk variants is related to cognitive
deterioration before the diagnosis of dementia, but
larger data sets are necessary to more precisely quan-
tify this effect in dementia-free individuals.References
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